JP2018514204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514204A5 JP2018514204A5 JP2017554350A JP2017554350A JP2018514204A5 JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5 JP 2017554350 A JP2017554350 A JP 2017554350A JP 2017554350 A JP2017554350 A JP 2017554350A JP 2018514204 A5 JP2018514204 A5 JP 2018514204A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cell
- car
- signaling domain
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1507368.7 | 2015-04-30 | ||
| GBGB1507368.7A GB201507368D0 (en) | 2015-04-30 | 2015-04-30 | Cell |
| PCT/GB2016/051235 WO2016174461A1 (en) | 2015-04-30 | 2016-04-29 | T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018514204A JP2018514204A (ja) | 2018-06-07 |
| JP2018514204A5 true JP2018514204A5 (enExample) | 2019-06-06 |
| JP6986449B2 JP6986449B2 (ja) | 2021-12-22 |
Family
ID=53488907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017554350A Expired - Fee Related JP6986449B2 (ja) | 2015-04-30 | 2016-04-29 | ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20180125890A1 (enExample) |
| EP (1) | EP3288567B1 (enExample) |
| JP (1) | JP6986449B2 (enExample) |
| KR (1) | KR20180020140A (enExample) |
| CN (1) | CN107771215A (enExample) |
| AU (1) | AU2016255611B2 (enExample) |
| BR (1) | BR112017023409A2 (enExample) |
| CA (1) | CA2982532C (enExample) |
| EA (1) | EA201792042A1 (enExample) |
| ES (1) | ES3018558T3 (enExample) |
| GB (1) | GB201507368D0 (enExample) |
| HK (1) | HK1252235A1 (enExample) |
| IL (1) | IL255186B (enExample) |
| SG (1) | SG11201708402UA (enExample) |
| WO (1) | WO2016174461A1 (enExample) |
| ZA (1) | ZA201706923B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| WO2018175988A1 (en) * | 2017-03-24 | 2018-09-27 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| AU2018341227B2 (en) * | 2017-09-27 | 2024-10-03 | Ohio State Innovation Foundation | Tissue factor-targeting CAR-NK and CAR-T cell therapy |
| GB201715918D0 (en) * | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
| GB201720949D0 (en) | 2017-12-15 | 2018-01-31 | Autolus Ltd | Cell |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| GB201804701D0 (en) * | 2018-03-23 | 2018-05-09 | Gammadelta Therapeutics Ltd | Lymphocytes expressing heterologous targeting constructs |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| CN110343712B (zh) * | 2018-04-04 | 2023-12-26 | 达仁生物科技有限公司 | 嵌合抗原受体和其治疗肺癌的方法 |
| CA3098128A1 (en) * | 2018-04-18 | 2019-10-24 | Ucl Business Ltd | Engineered regulatory t cell |
| CN108588023B (zh) * | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| CN110577932A (zh) * | 2018-06-07 | 2019-12-17 | 亘喜生物科技（上海）有限公司 | 一种脐带血来源的嵌合抗原受体t细胞 |
| WO2019242632A1 (en) * | 2018-06-19 | 2019-12-26 | 1§1Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| US20210238550A1 (en) | 2018-07-31 | 2021-08-05 | Thyas Co. Ltd. | METHOD FOR PRODUCING REGENERATED T CELL POPULATION VIA iPS CELLS |
| US12156888B2 (en) | 2018-08-07 | 2024-12-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T-cells for the treatment of bone metastatic cancer |
| DK3835415T3 (en) * | 2018-08-10 | 2025-01-02 | Univ Kyoto | Fremgangsmåde til fremstilling af cd3-positiv celle |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| BR112021005184A8 (pt) * | 2018-09-19 | 2022-08-16 | Lava Therapeutics B V | Imunoglobulina cd1d de dupla ação |
| CN109234236A (zh) * | 2018-09-29 | 2019-01-18 | 吉林大学第医院 | 一种嵌合抗原受体γδT细胞的制备方法 |
| KR20210087458A (ko) * | 2018-10-01 | 2021-07-12 | 아디셋 바이오, 인크. | 고형 종양 치료를 위한 조작된 및 비-조작된 γδ-T 세포에 관한 조성물 및 방법 |
| EA202190926A1 (ru) * | 2018-10-01 | 2021-06-25 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей |
| CN113508137B (zh) * | 2019-01-29 | 2024-12-20 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| US20220088074A1 (en) * | 2019-02-21 | 2022-03-24 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| SG11202109051PA (en) * | 2019-04-12 | 2021-10-28 | Phanes Therapeutics Inc | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof |
| AU2020261886A1 (en) * | 2019-04-22 | 2021-11-18 | Nanjing Legend Biotech Co., Ltd. | Engineered cells and uses thereof |
| CN113939302A (zh) | 2019-06-14 | 2022-01-14 | 赛雅思株式会社 | 医药组合物 |
| US20220259281A1 (en) * | 2019-06-21 | 2022-08-18 | Shattuck Labs, Inc. | Chimeric protein expressing t-cells |
| GB201909283D0 (en) * | 2019-06-27 | 2019-08-14 | Cancer Research Tech Ltd | Fusion proteins with enzyme activity |
| CN110981972B (zh) * | 2019-12-25 | 2022-09-30 | 华夏源（上海）细胞基因工程股份有限公司 | 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用 |
| WO2021176373A1 (en) * | 2020-03-03 | 2021-09-10 | Janssen Biotech, Inc. | ꝩδ T CELLS AND USES THEREOF |
| BR112022023371A2 (pt) | 2020-05-22 | 2022-12-20 | Chongqing Prec Biotech Co Ltd | Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica |
| IL299886A (en) | 2020-07-17 | 2023-03-01 | Instil Bio Uk Ltd | Receptors that provide targeted costimulation for host cell therapy |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| EP4355340A4 (en) | 2021-06-16 | 2025-05-21 | Instil Bio, Inc. | RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY |
| WO2023288278A1 (en) | 2021-07-16 | 2023-01-19 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
| CN113528455A (zh) * | 2021-07-19 | 2021-10-22 | 广州百暨基因科技有限公司 | 表达嵌合抗原受体的γδT细胞 |
| CA3233987A1 (en) * | 2021-10-06 | 2023-04-13 | Carl NOVINA | Engineered cytokine receptors for tunable adoptive cell therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2360046A1 (en) | 1999-01-28 | 2000-08-03 | Lawrence S. Lamb, Jr. | In vitro activated gamma delta lymphocytes |
| AU4816201A (en) | 2000-04-03 | 2001-10-15 | Hemosol Inc | Production of tcr gamma delta t cells |
| ES2302106T3 (es) | 2000-09-11 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Procedimiento de preparacion de derivados de bencimidazol-2-il quinolina. |
| WO2006006720A1 (ja) | 2004-07-13 | 2006-01-19 | Medinet., Co.Ltd | γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤 |
| DK1778836T3 (da) | 2004-08-19 | 2010-11-22 | Univ Cardiff | Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi |
| WO2008152822A1 (ja) | 2007-06-15 | 2008-12-18 | Medinet Co., Ltd. | 医薬 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014124143A1 (en) | 2013-02-06 | 2014-08-14 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| KR102238226B1 (ko) * | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| EP3925618A1 (en) * | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| CA2926859A1 (en) | 2013-10-25 | 2015-04-30 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta t cells for immunotherapy |
| WO2015066262A1 (en) * | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| WO2015075468A1 (en) * | 2013-11-21 | 2015-05-28 | Ucl Business Plc | Cell |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| JP2017524031A (ja) | 2014-07-09 | 2017-08-24 | ティーシー バイオファーム リミテッド | ガンマデルタｔ細胞およびその使用 |
| US11135245B2 (en) | 2014-11-17 | 2021-10-05 | Adicet Bio, Inc. | Engineered γδ T-cells |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| CN105158466B (zh) | 2015-05-05 | 2017-12-22 | 中国科学院广州生物医药与健康研究院 | 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法 |
-
2015
- 2015-04-30 GB GBGB1507368.7A patent/GB201507368D0/en not_active Ceased
-
2016
- 2016-04-29 US US15/567,165 patent/US20180125890A1/en not_active Abandoned
- 2016-04-29 EA EA201792042A patent/EA201792042A1/ru unknown
- 2016-04-29 HK HK18111473.3A patent/HK1252235A1/zh unknown
- 2016-04-29 AU AU2016255611A patent/AU2016255611B2/en active Active
- 2016-04-29 WO PCT/GB2016/051235 patent/WO2016174461A1/en not_active Ceased
- 2016-04-29 SG SG11201708402UA patent/SG11201708402UA/en unknown
- 2016-04-29 ES ES16720532T patent/ES3018558T3/es active Active
- 2016-04-29 JP JP2017554350A patent/JP6986449B2/ja not_active Expired - Fee Related
- 2016-04-29 CN CN201680024237.0A patent/CN107771215A/zh active Pending
- 2016-04-29 EP EP16720532.7A patent/EP3288567B1/en active Active
- 2016-04-29 BR BR112017023409A patent/BR112017023409A2/pt not_active Application Discontinuation
- 2016-04-29 CA CA2982532A patent/CA2982532C/en active Active
- 2016-04-29 KR KR1020177034648A patent/KR20180020140A/ko not_active Ceased
-
2017
- 2017-10-12 ZA ZA2017/06923A patent/ZA201706923B/en unknown
- 2017-10-22 IL IL255186A patent/IL255186B/en unknown
-
2021
- 2021-11-17 US US17/528,836 patent/US12331316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514204A5 (enExample) | ||
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| Lee et al. | Human γδ T cell subsets and their clinical applications for cancer immunotherapy | |
| Enqvist et al. | Coordinated expression of DNAM-1 and LFA-1 in educated NK cells | |
| EP3475446A1 (en) | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses | |
| Seddiki et al. | Human antigen‐specific CD4+ CD25+ CD134+ CD39+ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses | |
| JP2020058380A (ja) | キメラ抗原受容体及びその製造方法 | |
| BR112021002390A2 (pt) | processos para gerar células modificadas e suas composições | |
| JP2018532407A5 (enExample) | ||
| De Bousser et al. | T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) T cell therapy | |
| JP2016538855A5 (enExample) | ||
| RU2022102250A (ru) | Клетка | |
| JP2018517410A5 (enExample) | ||
| CN107206024A (zh) | 改变cart细胞中的基因表达及其用途 | |
| JP2022541181A (ja) | Ｔｃｒ遺伝子の単離方法 | |
| Cutmore et al. | Current perspectives on the use of off the shelf CAR-T/NK cells for the treatment of cancer | |
| Lu et al. | Hijacking TYRO3 from tumor cells via trogocytosis enhances NK-cell effector functions and proliferation | |
| EP4458419A3 (en) | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto | |
| US12178831B2 (en) | Techniques for generating cell-based therapeutics using recombinant T cell receptor genes | |
| Chauhan et al. | Harnessing NK cell checkpoint-modulating immunotherapies | |
| Michen et al. | Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94/NKG2A for expansion of functional primary natural killer cells with tolerance to self | |
| US20210290672A1 (en) | Regulation of tumor-associated t cells | |
| Maiorana et al. | CAR-T therapy in multiple myeloma: looking beyond | |
| US20230313140A1 (en) | Method for preparing t cells for adoptive t cell therapy | |
| Kim et al. | Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors |